PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT6573633

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
SIMON SHAW	02/19/2021
SOMASEKHAR BHAMIDIPATI	02/11/2021
VANESSA TAYLOR	02/09/2021

RECEIVING PARTY DATA

Name:	RIGEL PHARMACEUTICALS, INC.
Street Address:	1180 VETERANS BOULEVARD
City:	SOUTH SAN FRANCISCO
State/Country:	CALIFORNIA
Postal Code:	94080

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	17013034

CORRESPONDENCE DATA

Fax Number: (503)595-5301

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 5035955300

Email: kiana.luke@klarquist.com STEVEN J. BURGESS **Correspondent Name:**

Address Line 1: 121 SW SALMON STREET, SUITE 1600

Address Line 2: WORLD TRADE CENTER Address Line 4: PORTLAND, OREGON 97204

ATTORNEY DOCKET NUMBER: 7946-104441-02 NAME OF SUBMITTER: STEVEN J. BURGESS SIGNATURE: /Steven J. Burgess/ **DATE SIGNED:** 02/26/2021

Total Attachments: 2

source=Assignment#page1.tif source=Assignment#page2.tif

> **PATENT** REEL: 055424 FRAME: 0842

506526857

ASSIGNMENT

WHEREAS, we, Simon Shaw, of Oakland, California, Somasekhar Bhamidipati, of Foster City, California, and Vanessa Taylor, of San Francisco, have invented a certain invention as described in the following patent applications:

PCT Patent Application No. PCT/US2020/049540, filed on September 4, 2020, entitled "HETEROCYCLIC RIP1 KINASE INHIBITORS," and

U.S. Patent Application No. 17/013,034, filed on September 4, 2020, entitled "HETEROCYCLIC RIP1 KINASE INHIBITORS,"

which applications are collectively referred to as "the patent applications."

WHEREAS, Rigel Pharmaceuticals, Inc., a corporation organized under the laws of the State of Delaware, having a place of business at 1180 Veterans Boulevard, South San Francisco, California, 94080, desires to acquire an interest therein:

NOW, THEREFORE, for good and valuable consideration, the receipt of which is hereby acknowledged, we, Simon Shaw, Somasekhar Bhamidipati, and Vanessa Taylor, hereby sell, assign, and transfer to Rigel Pharmaceuticals, Inc., the full and exclusive right, title, and interest in and to the invention, the patent applications, and patent rights throughout the world, including foreign patent priority rights, the right to file and prosecute International Applications under the Patent Cooperation Treaty, and the right to file and prosecute applications under the European Patent Convention; the invention, the patent applications, and letters patent in this or any foreign country, and all corresponding non-provisional applications, divisions, continuations, continuations-in-part, reissues, and extensions thereof, to be held and enjoyed by Rigel Pharmaceuticals, Inc., for its own use and benefit, and for its successors and assigns, to the full end of the term for which letters patent may be granted by the United States or any foreign country, as fully and entirely as the same would have been held by us had this assignment and sale not been made, and covenant that we have full right so to do, and agree that we will communicate to Rigel Pharmaceuticals, Inc., or its successors and assigns, any facts known to us respecting the invention, and testify in any legal proceeding, sign all lawful papers, execute all divisional, continuing, and reissue applications, make all rightful oaths, and do everything possible to aid Rigel Pharmaceuticals, Inc., and its successors and assigns, to obtain and enforce proper patent protection for the invention in the United States or any foreign country.

RECORDED: 02/26/2021

SJB:jam 10/01/20 7946-104441-02 6449099.doc P.0341.06.US.UT

We confirm that, at the time the invention was made, we were under an obligation to assign the invention to Rigel Pharmaceuticals, Inc.

We hereby grant the law firm of Klarquist Sparkman, LLP, the power to insert on this Assignment any further information that may be necessary or desirable in order to comply with all applicable legal requirements, including the rules of the United States Patent and Trademark Office, for submitting and recording this document.

Executed at the place and date opposite our respective signatures below.

Simon Shaw

Dated: 2/19/2021

DocuSigned by:

DocuSigned by:

Somasekhar Bhamidipati

Dated: 2/11/2021

--- DocuSigned by:

Vanessa Taylor

Dated: 2/9/2021